Benzinga | Aug 26, 2021 04:56AM EDT

SVB Leerink Maintains Outperform on Ascendis Pharma, Raises Price Target to $182

SVB Leerink analyst Joseph Schwartz maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $178 to $182.